MedPath

Effects of Fasting Mimetic Diet on Nephropatic Patients

Not Applicable
Completed
Conditions
Renal Insufficiency, Chronic
Interventions
Dietary Supplement: Fasting mimetic diet
Registration Number
NCT04490252
Lead Sponsor
University of Roma La Sapienza
Brief Summary

Fasting mimetic diet (FMD) showed positive effects on cardiovascular risks. Purpose of the trial is to evaluate FMD effects on patients affected by chronic kidney disease (CKD), through the stimulation of kidney stem cells and improving cardiovascular and metabolic status.

From April 2018, the investigators enrolled 13 patients (7 male) with an history of primary glomerulonephritis (GMN) and an eGFR between 60 ml/min and 30 ml/min. Exclusion criteria are: age \<18 y.o., age\> 65 y.o., secondary GMN, severe heart failure (NYHA IV),ongoing infectious diseases, ongoing neoplasia, hepatic diseases, COPD, inflammatory bowel disease, history of stroke, history of acute coronary disease less than 3 months, pregnancy, refuse informed consent.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • History of primary glomerulonephritis
  • eGFR between 60 ml/min and 30 ml/min
  • age between 18-65 years old
Exclusion Criteria
  • secondary GMN
  • severe heart failure (NYHA IV)
  • ongoing infectious diseases
  • ongoing neoplasia,
  • hepatic diseases
  • COPD,
  • inflammatory bowel disease
  • history of stroke
  • history of acute coronary disease less than 3 months
  • pregnancy
  • refuse informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
FMDFasting mimetic dietFasting mimetic diet for 5 days, next cycle after 25 days of free diet
Primary Outcome Measures
NameTimeMethod
Blood stem cells level (CD133+, CD24+, CD45-, CD34+, CD309+) (%)Baseline to 6 months
Secondary Outcome Measures
NameTimeMethod
blood glucose (mg/dl)Baseline to 6 months
Flow-mediated dilation (%)Baseline to 6 months
eGFR using CKD-EPI and MDRD (ml/min/1,73 m2)Baseline to 6 months
Epicardial Adipose Tissue (cm)Baseline to 6 months
BMI (kg/m^2)Baseline to 6 months
Creatinine (mg/dl)Baseline to 6 months
Blood urea (mg/dl)Baseline to 6 months
Reactive C-protein (mg/L)Baseline to 6 months
Lipid profile: total cholesterol, LDL, HDL, triglyceride (mg/dl)Baseline to 6 months
iPTH (ng/ml)Baseline to 6 months
Total protein (g/L)Baseline to 6 months
Blood insulin (mcUI/ml)Baseline to 6 months
Intima-media thickness (mm)Baseline to 6 months
Blood uric acid (mg/dl)Baseline to 6 months
Renal resistive index (dimensionless)Baseline to 6 months
Beck depression inventory II (BDI-II) (0 to 63 points)Baseline to 6 months

Trial Locations

Locations (1)

Hospital "Umberto I", University of Rome "Sapienza"

🇮🇹

Roma, Lazio, Italy

© Copyright 2025. All Rights Reserved by MedPath